MB
MPM BioImpact Portfolio holdings
AUM
$577M
This Quarter Return
+8.2%
1 Year Return
+8.33%
3 Year Return
+241.63%
5 Year Return
+127.38%
10 Year Return
–
AUM
$667M
AUM Growth
+$667M
(+3.6%)
Cap. Flow
+$8.21M
Cap. Flow
% of AUM
1.23%
Top 10 Holdings %
Top 10 Hldgs %
55.8%
Holding
54
New
10
Increased
20
Reduced
7
Closed
11
Top Buys
| 1 |
Avidity Biosciences
RNA
|
$25.9M |
| 2 |
Rocket Pharmaceuticals
RCKT
|
$19.7M |
| 3 |
Twist Bioscience
TWST
|
$13.3M |
| 4 |
Aquestive Therapeutics
AQST
|
$8.95M |
| 5 |
Janux Therapeutics
JANX
|
$7.77M |
Top Sells
| 1 |
Alkermes
ALKS
|
$13.4M |
| 2 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$12.6M |
| 3 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$11M |
| 4 |
Xeris Biopharma Holdings
XERS
|
$10.9M |
| 5 |
Axsome Therapeutics
AXSM
|
$10.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Scholar Rock
SRRK
$3.3B
| – | – |
-1,028,330
| Closed | -$8.57M |
|
|
VERV
52
DELISTED
Verve Therapeutics
VERV
| – | – |
-638,163
| Closed | -$3.11M |
|
|
53
Xeris Biopharma Holdings
XERS
$1.27B
| – | – |
-4,830,526
| Closed | -$10.9M |
|
|
MORF
54
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| – | – |
-369,384
| Closed | -$12.6M |
|